Theravance Biopharma (TBPH) Cash from Financing Activities (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Cash from Financing Activities of -$5.6 million for Q1 2026, down 553.04% year-over-year from $1.2 million in Q1 2025, and down 274.04% quarter-over-quarter from -$1.5 million in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Cash from Financing Activities for 14 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 553.04% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at -$8.0 million (down 387.52% YoY), while the FY2025 annual figure was -$3.2 million, down 30.08% from the prior year.
- Cash from Financing Activities fell to -$5.6 million in Q1 2026 per TBPH's latest filing, from -$1.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $140000.0 in Q2 2022 and bottomed at -$722.0 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged -$55.8 million across 5 years, with a median of -$1.5 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 57728.57% — and 2024, when it surged 99.95%.
- Theravance Biopharma's Cash from Financing Activities stood at -$15.3 million in 2022, then sank by 100.28% to -$30.6 million in 2023, then jumped by 98.81% to -$365000.0 in 2024, then tumbled by 308.49% to -$1.5 million in 2025, then slumped by 274.04% to -$5.6 million in 2026.
- Business Quant data shows TBPH's Cash from Financing Activities at -$5.6 million in Q1 2026, -$1.5 million in Q4 2025, and -$400000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.19 Bn | 130.34 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.10 Bn | 77.11 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.16 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.76 Bn | 52.62 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.15 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.46 Bn | 27.62 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.38 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Theravance Biopharma | 882.73 Mn | 495.07 Mn | - | -967,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -967,000.00 |
| Mar 31, 2026 | -5.58 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Sep 30, 2025 | -400,000.00 |
| Jun 30, 2025 | -503,000.00 |
| Mar 31, 2025 | -854,000.00 |
| Dec 31, 2024 | -365,000.00 |
| Sep 30, 2024 | -372,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | -30.61 Mn |
| Sep 30, 2023 | -31.40 Mn |
| Jun 30, 2023 | -80.68 Mn |
| Mar 31, 2023 | -56.24 Mn |
| Dec 31, 2022 | -35.47 Mn |
| Sep 30, 2022 | -722.03 Mn |
| Jun 30, 2022 | 140,000.00 |
| Mar 31, 2022 | -1.45 Mn |
| Dec 31, 2021 | 149,000.00 |
| Sep 30, 2021 | -2.29 Mn |